Prosecution Insights
Last updated: April 19, 2026

Nurix Therapeutics Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
1
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18579114 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY LEESER, ERICH A 1622 Non-Final OA Jan 12, 2024
18213177 COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDS AND ANTIEMETIC AGENTS WELLS, LAUREN QUINLAN 1622 Non-Final OA Jun 22, 2023
17889062 COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE SAMSELL, RILLA MARIE 1624 Final Rejection Aug 16, 2022

Managing Nurix Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month